ENDRA Life Sciences Inc. Warrants
NDRAW
NDRAW was delisted on the 12th of May, 2022.
1 hedge funds and large institutions have $1K invested in ENDRA Life Sciences Inc. Warrants in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more capital invested
Capital invested by funds: $1K → $1K ($0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$237 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1K | +$237 | +360 | +26% |
|
NDRAW Hedge Fund Activity: Q2 2021 in Review
1 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences Inc. Warrants (NDRAW) for Q2 2021, worth a combined $1K — unchanged from a quarter earlier.
Fund positioning in NDRAW was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $237.
- 1 institutional investor held ENDRA Life Sciences Inc. Warrants (NDRAW) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $1K of ENDRA Life Sciences Inc. Warrants stock for Q2 2021, unchanged quarter-over-quarter.
- 0 funds opened new ENDRA Life Sciences Inc. Warrants positions in Q2 2021 and 0 closed out.
- The largest ENDRA Life Sciences Inc. Warrants buyer in Q2 2021 was UBS Group, an estimated $237 added.
Based on aggregated 13F filings for Q2 2021.